Citations

Clear

7732 citation(s) found for "Ma, Daniel".

Lysosomes as multifunctional hubs of CD8+ T cell regulation
Borges da Silva, Henrique , Dong, Haidong , Billadeau, Daniel D

Mayo Clinic

Journal of Cell Science | November 19, 2026 | Volume: 139 | Issue: 22 | Pages: No page available

10.1242/jcs.265033 | PMID 43055083 Get It

ABSTRACT Lysosomes have traditionally been recognized for their role in protein degradation. In CD8+ cytotoxic T lymphocytes (CTLs), most lysosomes represent a type of specialized lysosome-related organelle called a lytic granule (LG). LGs are comprised of lytic components, such as perforin (PRF1) and granzymes, that are required for the elimination of stressed, virus-infected or tumor cells. However, it is now well appreciated that lysosomes in CTLs have functions beyond cytotoxicity and serve as dynamic hubs for integrating signals driving cellular metabolism, mTORC1 signaling and autophagy. Together, this highly versatile organelle coordinates CTL activation, differentiation, memory formation and effector function. This Review examines the mechanisms by which lysosomes regulate LG biogenesis and secretion, autophagy, and metabolic reprogramming in CD8+ T cells. We additionally discuss how disruption of lysosomal pathways in CTLs impairs immune defense and contributes to immunodeficiency.
From Priority Questions to Registry-Nested Trials: An AJRR-C Road Map for Advancing Arthroplasty Research
Hannon, Charles P , Springer, Bryan D. , Huddleston, James I , Kremers, Hilal Maradit , Lewallen, David G , Berry, Daniel J

Mayo Clinic

Journal of Bone and Joint Surgery | November 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.2106/jbjs.26.01407 | PMID 43050508 Get It

Background: The American Joint Replacement Research-Collaborative (AJRR-C) is a National Institutes of Health-funded P30 Core Center for Clinical Research and seeks to accelerate practice-changing arthroplasty research by leveraging the American Joint Replacement Registry (AJRR) and shared multicenter research infrastructure. The AJRR-C convened 2 complementary meetings to establish a scalable coordinated pathway from the identification of high-priority clinical questions to the initiation of prospective studies. Methods: In July 2025, leaders from The Hip Society, The Knee Society, the American Association of Hip and Knee Surgeons, the AJRR, the Orthopaedic Research and Education Foundation, and the broader research community identified and prioritized clinical research questions regarding infection, perioperative management, new technologies, surgical techniques, implants, and quality. In April 2026, orthopaedic surgeons, methodologists, and artificial intelligence experts reconvened to evaluate contemporary approaches for addressing these priorities. Results: A central theme of the meetings was the importance of utilizing a fit-for-purpose approach in which study design is tailored to the clinical question, available data, and potential sources of bias. Clinical questions with clear equipoise and feasible interventions may warrant randomization, whereas questions involving rare outcomes, rapidly evolving technologies, surgeon preferences, or long-term surveillance may be better addressed with observational studies. Participants emphasized the need for a robust, sustainable network for arthroplasty clinical trials that provides the shared infrastructure necessary for coordinated site engagement, standardized data definitions, reliable longitudinal follow-up, and AJRR linkage across multicenter trials. Two new AJRR-nested randomized trials arose from the priority-topics meeting, and their development demonstrates the potential of the AJRR-C consensus model to translate research priorities into practice-changing evidence generation. Conclusions: The AJRR-C established a coordinated pathway from the prioritization of research to the implementation of multicenter studies to address high-priority arthroplasty research questions. Sustaining this model requires continued collaboration among orthopaedic societies, investigators, methodologists, and the AJRR, as well as reliable funding mechanisms.
Stepping up liver care: Rethinking alcohol treatment in chronic liver disease
Daniel, P Vineeth

Mayo Clinic

Hepatology | November 16, 2026 | Volume: 84 | Issue: 6 | Pages: 1607-1608

10.1097/hep.0000000000001873 | PMID 43037584 Get It

Can Pediatric Emergency Medicine Clinicians Identify Solid Organ Injuries Using Contrast‐Enhanced FAST in Abdominal Trauma?
Leff, Rebecca , Kummer, Tobias , Nagler, Joshua , Lev, Hannah J , Mooney, David , Molinari, Daniel Fiterman , Gravel, Cynthia A

Mayo Clinic

Journal of Clinical Ultrasound | November 16, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/jcu.70471 | PMID 43035326 Get It

ABSTRACT Background Contrast‐enhanced FAST (cFAST) has demonstrated superior sensitivity to B‐mode FAST for detecting solid organ injury in blunt abdominal trauma, yet no prior study has evaluated cFAST image interpretation by pediatric emergency medicine (PEM) clinicians. We evaluated the sensitivity and specificity of cFAST interpretation for solid organ injuries by PEM clinicians following a web‐based didactic. Methods In this prospective, single‐center study (February–May 2026), PEM clinicians credentialed in B‐mode FAST without prior cFAST training completed a web‐based didactic. Participants interpreted 12 simulated cases (25 cine clips), evaluating 41 organs (15 injured, 26 non‐injured), all reviewed by a cFAST expert or cFAST‐trained pediatric radiologist with CT confirmation. Pooled organ‐level sensitivity and specificity were calculated with clustering correction using robust standard errors. Results Among 41 participants, 1681 organ‐level decisions were analyzed. Pooled sensitivity was 87.97% (95% CI: 84.96%–91.09%), specificity was 89.12% (95% CI: 86.53%–91.78%), negative predictive value (NPV) was 92.77% (95% CI: 90.99%–94.59%), and positive predictive value was 82.34% (95% CI: 78.68%–86.17%). False‐negative decisions occurred in 4.4% ( n = 74/1681). Conclusion After a web‐based curriculum, PEM clinicians achieved high sensitivity, specificity, and NPV with few missed injuries, supporting future investigation of cFAST as an adjunctive screening tool in pediatric blunt abdominal trauma risk‐stratification assessments.
Remote patient management reduces liver-related hospitalizations in patients with acutely decompensated cirrhosis
Calleri, Alberto, Hara, Kamalpreet S. , Prusch Fernandes, Gabriel, Williams, Katherine M, Kloft-Nelson, Sara M, Leuenberger, Angela M, Sangaralingham, Lindsey R. , Rattan, Puru , Penrice, Daniel

Mayo Clinic

Hepatology | November 10, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/hep.0000000000001911 | PMID 43007295 Get It

Background: Patients with decompensated cirrhosis experience frequent hospitalizations, yet evidence supporting remote post-discharge care remains limited. This study assessed the impact of cirrhosis-specific Remote Patient Management (CiRPM) program following hospitalization for acutely decompensated (AD) cirrhosis. Methods: Adults hospitalized for AD cirrhosis were included in a three-cohort observational study comparing CiRPM (2021-2024) with contemporary (C-control) and historical controls (H-control, 2018-2019). CiRPM enabled vital-sign and symptom transmission with 24/7 virtual nursing support. Subgroup analyses were conducted by disease etiology, CLIF-C AD score, and decompensation type. IPTW was used to adjust for confounding, and time-to-event outcomes were analyzed using Cox proportional hazards models. Results: Among 430 patients (156 CiRPM, 152 H-control, 122 C-control), mean age was 59 years, 65% had alcohol-associated liver disease (ALD), CLIF-C AD score of 56. CiRPM was associated with lower 90-day liver-related readmissions versus C-control (39% vs. 58%; HR 0.57, p =0.01) and a similar trend versus H-control (39% vs. 52%; HR 0.67, p =0.07). Associations were stronger among patients with CLIF-C AD ≥60 (HR 0.43 vs. H-control, p =0.005; HR 0.51 vs. C-control, p =0.02). Among ALD patients, fewer fluid-related readmissions (OR 0.40 and 0.37; both p <0.001) and recurrent hospitalizations (OR 0.51; p =0.001 and p =0.002) were observed in the CiRPM group. In non-ALD patients, hepatic encephalopathy readmissions were lower (OR 0.29, p =0.004; OR 0.36, p =0.02). Mortality did not differ across groups. Conclusion: CiRPM enrollment was associated with fewer liver-related hospitalizations, particularly among patients with ALD and CLIF-C AD ≥60, supporting targeted remote management as a scalable post-discharge strategy for this high-risk population.
False-positive beta-2 transferrin test not associated with a postoperative lumbar cerebrospinal fluid leak: A case report
Dufault, Matthew , Dhupati, Pooja , Jeger, Jonathan L , Lettieri, Salvatore C. , Gridley, Daniel, Feiz‐Erfan, Iman

Mayo Clinic

Surgical Neurology International | November 6, 2026 | Volume: 17 | Issue: No issue available | Pages: 638

10.25259/sni_1181_2026 Get It

Background: Lumbar laminectomy and fusion may be complicated by cerebrospinal fluid (CSF) leaks. Beta-2 transferrin (B2T) is a diagnostic marker for CSF that has been mostly studied in the context of cranial CSF leak, but its accuracy in diagnosing spinal leaks is less certain. Case Description: A 59-year-old male with chronic back pain and lumbar stenosis underwent a multi-level laminectomy and fusion with a watertight repair of incidental durotomy. Postoperatively, he developed a non-healing surgical wound and persistent high drain output with fluid testing positive for B2T. However, the patient had no clinical symptoms or signs of CSF leak and repeated wound exploration showed no leak. The wound became infected and, due to poor healing, the patient underwent a secondary closure with a negative pressure treatment dressing. Multiple intraoperative dressing changes did not disclose a CSF leak despite the fact that a repeat B2T in the wound fluid remained positive. Conclusions: This report describes a case of false-positive B2T in a patient after lumbar spine surgery. This case highlights the fact that a positive B2T measured in spinal wound fluid may not be diagnostic of a CSF leak. Possible sources of false-positive B2T laboratory results are discussed in this paper.
Validation of plasma biomarker immunoassay‐based models for predicting brain amyloid positivity in cognitively impaired individuals
Syrjanen, Jeremy A. , Figdore, Daniel J. , Griswold, Michael , Wiste, Heather J. , Dierkhising, Ross , Kremers, Walter K. , Lachner, Christian , Graff‐Radford, Neill R. , Day, Gregory S. , Graff‐Radford, Jonathan , Jack, Clifford R. , Knopman, David S. , Petersen, Ronald C. , Bornhorst, Joshua , Algeciras‐Schimnich, Alicia , Initiative, for the Alzheimer’s Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | November 5, 2026 | Volume: 22 | Issue: 11 | Pages: No page available

10.1002/alz.71946 | PMID 42982748 Get It

Abstract INTRODUCTION Combining Alzheimer's disease blood biomarkers may improve prediction of amyloid positivity (A+) compared with single biomarkers. METHODS Logistic regression models using plasma phosphorylated tau 217 (p‐tau217), amyloid beta (Aβ) 42, and Aβ40 were developed in cognitively impaired (CI) participants from Mayo Clinic Rochester (MCR) and validated in Alzheimer's Disease Neuroimaging Initiative (ADNI) and Mayo Clinic Florida (MCF) cohorts. Performance was measured by area under the curve (AUC) and Probability of Amyloid Positivity Score (PAPS). RESULTS Plasma p‐tau217 alone showed high AUC (95% confidence intervals) across cohorts MCR, 0.928 (0.900–0.953); ADNI, 0.938 (0.915–0.959); MCF, 0.935 (0.893–0.970). Adding Aβ42 to regression models yielded marginal model improvement MCR, 0.940 (0.915–0.963); ADNI, 0.945 (0.922–0.965); MCF, 0.960 (0.925–0.986). Utilization of two cutpoints (≥ 90% sensitivity and specificity), yielded ≤ 10% intermediate results for p‐tau217, and ≤ 8% for p‐tau217+Aβ42. Addition of Aβ40 did not improve models’ performance. DISCUSSION An immunoassay‐based p‐tau217 PAPS model accurately predicted amyloid positivity across independent CI cohorts and achieved confirmatory‐test performance with two cutpoints. The added value of Aβ42 was modest and cohort dependent, supporting the potential of use of p‐tau217–based PAPS in clinical workflows.
Cost-Effectiveness of Anterior and Posterior Surgical Approaches for Cervical Spondylotic Myelopathy: An Economic Evaluation of a Randomized Clinical Trial
Whitmore, Robert G. , Miranda, Stephen P. , Bydon, Mohamad , Dholakia, Ruchita, Moriarty, James P. , Borah, Bijan J. , Kanter, Adam S., Mummaneni, Praveen V. , Bisson, Erica F. , Harrop, James S., Magge, Subu N., Heary, Robert F., Fehlings, Michael G. , Albert, Todd J. , Arnold, Paul M., Riew, Kiehyun Daniel , Steinmetz, Michael P., Benzel, Edward, Wang, Marjorie C., Heller, John G., Ghogawala, Zoher

Mayo Clinic

Neurosurgery | November 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1227/neu.0000000000004268 | PMID 42975416 Get It

BACKGROUND AND OBJECTIVES: Surgery for cervical spondylotic myelopathy improves quality of life but remains expensive. We conducted a cost-effectiveness analysis of patients treated with anterior cervical diskectomy/fusion (ACDF), posterior cervical decompression/fusion (PCDF), and laminoplasty (LP) in the Cervical Spondylotic Myelopathy Surgical (CSM-S) Trial, a randomized trial comparing surgical approaches for cervical spondylotic myelopathy. METHODS: In the trial, patients were randomized (2:3) to anterior (ACDF) or posterior surgery (LP or PCDF, at surgeon's discretion). A cost-effectiveness analysis was performed from a societal perspective with a 1-year time horizon, including only US patients as-treated. Cumulative costs were estimated using patient data on utilization and lost productivity using a human capital approach. Direct costs were calculated using 2022 Medicare rates for professional fees and cost-to-charge ratios for hospital services. Quality-adjusted life-years (QALYs) were calculated from patient responses to the EuroQol-5-Dimensions instrument at baseline and 3, 6, and 12 months postoperatively. Incremental cost-effectiveness ratio analysis was performed with bootstrapping to address uncertainty. RESULTS: Of 163 total patients enrolled in the CSM-S Trial, 153 from the United States (mean age, 62 years; 80 (52%) female) were included as-treated (ACDF = 61, PCDF = 64, LP = 28) in a cost-effectiveness analysis. Economic data were not available for 9 patients. The remaining 144 patients treated (ACDF = 55, PCDF = 61, LP = 28) had cost data through a 1-year follow-up. Mean hospitalization costs were higher after PCDF than ACDF and LP ($33 410 vs $26 468 vs $25 550; P < .001). Mean total costs were higher after PCDF than ACDF and LP ($62 383 vs $53 074 vs $47 426; P = .017). LP yielded greater QALY gains than ACDF (0.792 vs 0.732; P = .08) and PCDF (0.792 vs 0.698; P = .01). At a willingness-to-pay threshold of $150 000/QALY-gained, the probability that LP was cost-effective compared with PCDF was 99.7% and the probability compared with ACDF was 96%. CONCLUSION: In the CSM-S Trial, LP yielded greater 1-year quality-of-life improvements at lower costs than PCDF and ACDF.
Editorial: Hormonal challenges and therapeutic strategies in sports medicine
Lazarev, Artemii Mikhailovich , Kelly, Daniel M. , Hackney, Anthony C.

Mayo Clinic

Frontiers in Sports and Active Living | November 3, 2026 | Volume: 8 | Issue: No issue available | Pages: No page available

10.3389/fspor.2026.2028411 Get It

Comparative survival and time toxicity outcomes of CAR-T versus bispecific antibody therapies in relapsed/refractory FL
Ahmed, Nausheen , Nogueira Serodio, Alline , Villasboas, Jose Caetano , Sharp, John , Voorhees, Timothy J , Houshyar, Samin , Wallace, Danielle S , Wagner, Charlotte , Bock, Allison M , Brooks, Taylor R , Al Any, Haya, Rajab, Mohamed , Gupta, Supriya , Karmali, Reem , Trotier, Daniel C , Pophali, Priyanka , Ricker, Edd , Cherng, Hua-Jay J , Torka, Pallawi , Trabolsi, Asaad , Schatz, Jonathan H , Gupta, Arjun

Mayo Clinic

Blood Advances | October 30, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/bloodadvances.2026020899 | PMID 42962270 Get It

Chimeric antigen receptor T-cell (CAR-T) and CD20xCD3 bispecific antibody (BsAb) therapies are both effective for relapsed/refractory (R/R) follicular lymphoma (FL), but comparative real-world survival outcomes and time toxicity have not been characterized. We performed a multicenter retrospective study of 228 patients with R/R FL treated with standard-of-care CAR-T (n = 141) or BsAb (n = 87) across 17 U.S. academic centers in the third-line or later setting. Progression-free survival (PFS) and overall survival (OS) were stratified by 2 or ≥3 prior lines of therapy (LOT2 or LOT3+), including propensity matching. Time toxicity was measured by physical health care contact days. Median PFS was not reached (NR) with CAR-T and 581 days with BsAb in the LOT2 cohort (p &lt; .0001), and was NR with CAR-T and 584 days with BsAb in the LOT3+ cohort (p = .0064). CAR-T recipients were younger (p &lt; .0001) and had better performance status (p = .007) but were more refractory to prior LOT (p = .017). PFS advantages of CAR-T were independent of these differences. OS did not differ between treatment groups. CAR-T had significantly greater time toxicity over the first year, with higher mean contact days than BsAb in both the LOT2 (58 vs 44) and LOT3+ (69 vs 49) cohorts. In this large multicenter cohort of patients with R/R FL, CAR-T was associated with superior PFS but greater time toxicity compared with BsAb therapy. These findings provide real-world outcomes data and time toxicity benchmarks to support treatment sequencing decision-making in R/R FL.